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O R I GINAL ARTICLE

Evaluating the Prediction of Breast Cancer Survival Using Lymph Node Ratio
Man Hung1,2,3, Julie Xu1, Dominique Nielson1, Jerry Bounsanga1, Yushan Gu1, Alec Roger Hansen1, Maren Wright Voss1
Department of Orthopaedics and 2Study Design and Biostatistics Center, University of Utah School of Medicine, Salt Lake City; 3Huntsman Cancer
Institute, University of Utah, Salt Lake City, USA
1

Purpose: Previous oncological studies showed that lymph node
ratio (LNR) (ratio of number of lymph nodes that tested positive
for metastasis to the total number of lymph nodes examined) is a
negative indicator of cancer survival. The American Joint Committee
on Cancer (AJCC) staging system incorporates tumor size,
lymph node involvement, and metastasis in a comprehensive
model of cancer progression, but LNR alone has been shown to
outperform the AJCC system in prognostic and survival predictions for various types of cancer. The effectiveness of LNR has
not been evaluated in breast cancer staging. Evaluating LNR for
predicting cancer staging in breast cancer has the potential to
improve treatment recommendations. Methods: The Surveillance,
Epidemiology, and End Results dataset was used to identify
10,655 breast cancer patients who underwent nodal evaluation
from 2010 to 2013, and their LNRs were calculated. Descriptive
statistics of lymph node evaluation in the patients are provided.
Logistic regression with LNR as the continuous independent

INTRODUCTION
Cancer is the second leading cause of death in the United
States. A total of 1,685,210 new cancer cases were expected to
be diagnosed in 2016, with 595,650 expected deaths [1]. Of
these, 249,260 newly diagnosed breast cancer cases were estimated, with 40,890 expected deaths. Breast cancer makes up
14.79% of the total expected cancer diagnoses and 6.86% of
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variable was conducted to determine whether LNR could predict
cancer progression, coded as regional or distant. Analysis was
conducted using SPSS version 24. Results: Patient’s mean age
was 59.43± 18.62. Logistic regression analysis revealed that for
every 1.3% increase in LNR, the odds of falling into the distant
stage of the TNM staging system increased by 13.7% (odds ratio,
14.73; 95% confidence interval, 12.00–18.08). Conclusion: LNR,
while correlated with breast cancer staging, serves as a better
predictor of survival. Precision staging can influence treatment
modality, and improved treatments can significantly improve
quality of life. Additional research and diagnostic examinations
using LNR as a potential tool for accurate staging in breast cancer patients are warranted.

Key Words: American Joint Committee on Cancer, Breast neoplasms, Lymph
node, Neoplasm staging, Survival

the total expected cancer related deaths for both sexes in the
United States. In women, breast cancer is expected to account
for 29% of new cancer diagnoses. While breast cancer patients
have increased survival rates in comparison with other cancer
types, the high incidence places breast cancer as one of the
most common causes of cancer-related deaths [1]. Since 1990,
the rate of mortality from breast cancer has been declining
due to improved treatments and early detection methods [2].
These have been shown to be important predictors of survival,
as early detection has been associated with reduced breast
cancer morbidity and mortality rates [3].
A key component in identifying the appropriate treatment
course is an evaluation of the cancer at the time of diagnosis
[4]. Breast cancer staging is a method of determining severity
of the disease and may include a physical examination of the
skin, mammary glands, and lymph nodes, with the axillary,
supraclavicular, and cervical nodes as the primary nodes of
evaluation [5]. Different methods exist for classifying clinical
and pathological findings into stages, though the most commonly used guidelines in the world are from the American
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Joint Committee on Cancer (AJCC) [6]. The AJCC staging
system is standardized, with specifically defined criteria for
each known stage of breast cancer. The system has traditionally included the size of the tumor (T), the extent of spreading
to the regional lymph nodes (N), along with the presence of
metastasis to relatively distal areas (M) with numbers and
lowercase letters for subtyping as needed (e.g., T1a, T1N2M0).
The tumor can be measured based on its clinical features, appearance on imagery, size, and growth. Extent of spreading to
regional lymph nodes is typically staged by pathology of tissue
samples obtained by biopsy, which is known as pathologic
staging (pN). pN staging is the most accurate way to assess
nodal involvement because of the distinctive histological profiles of tumor cells. Collectively, these categories coupled with
the metastasis staging are known as the TNM staging system.
Even though the extent of metastasis is critical to assess a
patient’s prognosis, the classifications have proven to be difficult to define further than “evidence of tumor cells in areas
beyond the tumor site and regional lymph nodes.” This may
be due to the lack of clinical presentation of the pathological
M0 stage which can only be proven at autopsy. The 7th edition of the AJCC’s staging system raised this issue, yet the
staging for this category remained the same in the AJCC’s 8th
edition. Also mentioned were isolated tumor cells which are
single or small clusters of submillimeter tumor cells which
could be indicative of distant metastasis. These have not been
assessed for their role in cancer prognosis. With these continually unaddressed gaps in classification and additions to treatment protocols such as neoadjuvant therapy and multigene
panel screening, it is important to consider the use of complementary staging systems. The AJCC released the 8th edition
of its cancer staging manual in 2017 with major changes recommended for breast cancer staging [7,8]. The new consensus
staging system maintained the TNM staging but added increased details of tumor dimension parameters, consideration
of neoadjuvant therapy, and adjustments for multigene panels
for cancers with known genetic etiologies that allow more
flexibility and precision for breast cancer staging. Breast cancer subtypes were categorized by involvement of several hormone receptors which are commonly implicated in breast
cancer: human epidermal growth factor receptor 2 (HER2),
estrogen receptor (ER), and progesterone receptor (PR) [9].
Gándara-Cortes et al. [10] elucidated targeted and sensitive
treatments for cancers characterized by the involvement of
these receptors. Prognosis generally tended to be worse for
those diagnosed with triple-negative (HER2–/ER–/PR–) and
HER2-positive breast cancers, though cases within a specific
subtype will vary somewhat in presentation [11,12]. This
combined TNM and subtype staging system is better at pre-
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dicting survival for breast cancer than either staging system
alone [13], indicating that even the most updated version of
the AJCC manual needed the extra nuances of a supplementary staging system.
The addition of new staging criteria reflects an awareness of
concerns with the TNM approach, not just in breast cancer
but in multiple areas of oncology. Recently, the evaluation of
lymph node ratio (LNR) in gastric cancer staging was shown
to outperform the 7th edition guidelines of the AJCC’s TNM
staging system in sensitivity measures and overall survival
[14]. LNR also proved useful in the prognosis of postsurgical
pancreatic cancer patients as one of the most powerful predictors of survival time [15]. The 7th edition of the AJCC’s staging system requires the examination of 15 lymph nodes for
accurate staging and classifies stage by location of the involved
nodes. Yet, the examination of 15 lymph nodes is often not
performed as some nodes are unavailable for resection, resulting in under-staging. Increased identification of involved
nodes and surgical resections of these nodes resulted in increased staging accuracy and colon cancer survival prediction
[16]. Inadequate analysis of lymph node involvement is a result of certain types of operations or a tumor with few local
lymph nodes for assessment. LNR has been used to augment
staging determination and successfully predict prognosis [17].
Even in cases where sufficient nodal resection was performed,
LNR has been shown to be superior to the AJCC’s staging system via the assessment of the number of positive lymph nodes
for predicting prognosis in colon cancer [18]. Survival rates
predicted with LNR, metastatic lymph nodes, and log odds of
positive lymph nodes as the staging method were superior to
the AJCC’s 7th edition TNM staging system in rare perihilar
cholangiocarcinoma as well [19].
There is evidence of the prognostic value in using LNR to
predict breast cancer survival from multiple small studies
(sample sizes of less than 1,800) [20] and limited studies of
larger size [21,22]. There are a number of factors that can interfere with the value of LNR as a useful tool for prognosis in
breast cancer, including very large tumor sizes or advanced
disease, very-early stage disease, residual disease, or the use of
neoadjuvant therapy which can interfere with nodal evaluation [23], though other research shows LNR is effective for
prognostic prediction of high-risk breast cancers, even when
neoadjuvant therapy is used [24]. In one study combining
multiple cancer trials for an overall analysis of over 7,000
breast cancer patients, LNR was useful for prognosis in a subset of patients with 1–3 affected lymph nodes [25]. The effectiveness of LNR as a prognostic indicator has resulted in suggestions for inclusion of LNR in breast cancer staging [21].
Newer research as well as AJCC’s 8th edition staging system
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has focused on breast cancer subtypes as an adjunct to survival prediction and will be an important part of prospective
studies. However, the recent development of assays and imaging approaches to identify the genetic subtypes are still under
development and range in both cost and availability [10,26,
27], making large scale analysis inaccessible at present. The
purpose of this study was to access the large number of samples available in a national cancer data registry to evaluate the
effectiveness of LNR in predicting breast cancer survival compared to TNM staging.

METHODS
The study employed a retrospective analysis of The Surveillance, Epidemiology, and End Results (SEER) dataset. The
SEER dataset collects information from 12 population-based
cancer registries which comprise 14% of the United States
population. Patient demographic information, cancer diagnosis, and clinical indicators such as primary tumor size, grade,
and extension were obtained on 10,651 breast cancer patients
who underwent nodal evaluation between 2010 and 2013.
These characteristics were examined and reported with deTable 1. Demographics of patients in the SEER population (n= 10,655)
Variable
Age (yr)*
Sex
Female
Male
Race
White
Black
Asian or Pacific Islander
Other
Unknown
Location
San Francisco
Connecticut
Detroit
Hawaii
Iowa
New Mexico
Missing
Breast subtype
HER2+/HR+
HER2+/HR–
HER2–/HR+
Triple-negative
Missing

No. (%)
59.43± 18.62
10,523 (98.8)
132 (1.2)
8,426 (79.1)
1,201 (11.3)
883 (8.3)
60 (0.6)
85 (0.8)
9 (0.1)
2,728 (25.6)
3,252 (30.5)
1,047 (9.8)
2,233 (21.0)
1,382 (13.0)
4 (0.1)
1,172 (11.0)
519 (4.9)
7,285 (68.4)
1,189 (11.1)
490 (4.6)

SEER = Surveillance, Epidemiology, and End Results; HER2 = human epidermal growth factor receptor 2; HR= hormone receptor.
*Mean± SD.
https://doi.org/10.4048/jbc.2018.21.e35

scriptive statistics (Table 1).
The definitions in the SEER summary staging manual were
used to distinguish each summary stage of breast cancer. The
localized stage cases were excluded from analysis because the
localized stage is the only stage aside from the in situ stage that
does not include any measurable or significant degree of
lymph node involvement. The intrinsic nature of these stages
precludes their ability to participate in the evaluation of a
lymph node-based staging system. SEER defines regional
lymph nodes as the most proximal lymph nodes which serve
as immediate drainage sites for the site of the tumor and are
therefore good indicators for the metastatic behavior of the
cancer. For tumors of the breast, these include the axillary
lymphatic plexus, paramammary lymph nodes, and interpectoral axillary lymph nodes.
Metastasis classifications are binary: M0 (no distant metastasis) or M1 (distant metastasis). LNR was calculated as the
number of lymph nodes tested positive for metastasis after resection divided by the total number of lymph nodes that were
examined. Local, regional, and distant SEER categorizations
are determined by the TNM staging system and incorporate
factors of tumor size, multiplicity, depth of invasion, extension
to regional or remote areas, and histologic grade, in addition
to lymph node involvement. Independent sample t-tests were
run to test the hypothesis that staging and LNR are each associated with survival months. Correlational analysis was conducted to examine the relationship between LNR and TNM
staging. Logistic regression was performed using SPSS version
24 (IBM Corp., Armonk, USA) to identify whether LNR and
TNM staging could predict survival months, and whether
LNR could predict cancer staging as either local, regional, or
distant.

RESULTS
There were 10,523 women (98.8%) and 132 men (1.2%) included in the study. Patient’s mean age was 59.43 ± 18.62
(Table 1). There were 267 individuals under age 35 years; aged
35–54 years, 3,848; aged 55–75 years, 5,117; and over age 75
years, 1,423. Only two patients were in the localized group,
thus these cases were excluded due to the small sample size. A
total of 9,736 individuals (91.4%) were identified to be in the
regional cancer stage group, and 913 (8.6%) in the distant
cancer stage group (Figure 1). There were 7,423 cases (59.7%)
that had 15 or fewer nodes examined (Table 2). A chi-square
test was performed but no relationship was found between
age and LNR (χ2(3, N= 10,647)= 5.03; p= 0.170).
LNR and TNM staging for the classification of cases into either regional or distant cancer stages had a Spearman’s rho of
http://ejbc.kr
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10,000

Table 2. Number of nodes examined and frequency of positive nodes
for patients in the SEER

9,736

9,000

No. of nodes
examined

8,000
No. of cases

7,000
6,000
5,000
4,000
3,000
2,000
1,000

913
2

1–5
6–10
11–15
16–20
21–25
> 25
Missing

No. (%)

No. of positive
nodes

No. (%)

3,014 (28.3)
1,970 (18.5)
2,439 (22.9)
1,747 (16.4)
873 (8.2)
607 (5.7)
1 (0.0)

1–5
6–10
11–15
16–20
21–25
> 25
Missing

8,755 (82.2)
1,086 (10.2)
457 (4.3)
202 (1.9)
85 (0.8)
63 (0.6)
3 (0.0)

SEER= Surveillance, Epidemiology, and End Results.

0
Local

Regional

Distant

Breast cancer stage

Figure 1. Distribution of the Surveillance, Epidemiology, and End Results population for three progressions of breast cancer stage.

0.237, which was a small but significant correlation (p <
0.001). LNR was negatively correlated with survival months
(r= –0.113, p< 0.001) such that a lower ratio of positive nodes
resulted in longer survival months. Linear regression analysis
found that LNR was a stronger predictor of survival months
(β = –0.113, p < 0.001, r2 = 0.013) than TNM staging (β =
–0.050, p< 0.001, r2 = 0.002) for both regional and distant cancer stages (Table 3). Other multivariate models were tested,
including the addition of age at diagnosis and breast cancer
subtypes, but these variables did not alter the significance of
LNR in predicting survival months (results available upon request). LNR, while more predictive of survival months, was
related to TNM staging as logistic regression analysis revealed
that for every 1% increase in LNR, the odds of falling into the
distant cancer stage of the TNM staging system increased by
13.7% (odds ratio, 14.73; 95% confidence interval, 12.00–
18.08).

DISCUSSION
In this study, we sought to evaluate the prognostic value of
LNR within the breast cancer node positive cohort of the
SEER dataset in comparison to the survival prediction value
of the TNM staging system in SEER. It is well-established that
LNR can be a strong prognosis factor for several cancer types
[18]. More specifically, the prognostic use of LNR in breast
cancer has been shown to be a significant predictor of patient
overall survival, spanning all stages of breast cancer and various treatment types [20,22,28]. The present analysis used a
larger cohort of the SEER cancer registry than previous studies to compare the predictive value of LNR to TNM staging in
breast cancer survival for a diverse patient population, which

Table 3. Regression analyses: LNR and staging on survival months

Intercept of LNR
LNR
Intercept of regional/
distant stage
Regional/distant stage

β

Standard
error

24.133
–4.986
22.451

0.209
0.424
0.140

–11.751 < 0.001 0.013

–2.456

0.477

–5.154 < 0.001 0.002

t

p-value

r2

LNR= lymph node ratio.

is necessary for the findings to reflect the impact on the population at large.
We found that while LNR and TNM cancer staging have a
small but significant correlation, LNR was a better predictor
of survival than TNM. Our results, while consistent with previous studies that showed LNR may be warranted as a superior method of breast cancer prognosis, also found that LNR
exponentially increases the odds of falling into the distant
stage of the TNM cancer staging system. This association between LNR and distant stage TNM potentially explains the
higher prediction value of LNR over TNM staging.
The present study on a broad population of over 10,000
breast cancer patients evaluated whether LNR would be a useful prognostic indicator for today’s oncology providers. LNR
was able to provide a greater prediction of overall survival
than TNM staging, though the r2 value suggested that just
over 1% of the variation in survival months could be explained by LNR. While statistically significant, this level of
prediction may not be clinically meaningful or relevant for
treatment considerations for cases without node involvement,
or node-negative cases. This finding was consistent with other
LNR analyses that suggested only a small, defined subpopulation of breast cancer patients would benefit from the use of
LNR [25]. The analysis could have benefited from the consistent implementation of active post-study follow-up. Several
SEER regions input survival as a “presumed alive” date (no
death certificate or autopsy of patient during the study period)

http://ejbc.krhttps://doi.org/10.4048/jbc.2018.21.e35
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as the study end date, which was December 31, 2013. Other
regions proceeded with active follow-up and gave “date of last
contact” (with the research staff) as date of survival.
To incorporate LNR meaningfully into clinical practice, the
relationship between ratios and changes in ability to predict
overall survival must be defined. The AJCC reviews their
guidelines among multitudes of researchers and physicians to
update the system’s parameters on a regular basis. Reviews
have found the range of LNR between 0.20 and 0.65 to be the
most common cutoff points for increases and decreases in
overall survival [29]. Future studies should investigate and
suggest guidelines for evaluating these ratios.
Broad level analysis is limited by the inclusion of almost all
breast cancer types and levels of disease progression, which
are factors that can inhibit the usefulness of LNR in survival
prediction [23]. It should be understood that the patient population chosen for analysis excluded those with in situ and localized stage diagnoses due to the nature of the lymph node
biopsy procedure. Including subtype in the analysis did not
alter the significance of LNR as a predictor of survival months.
Additionally, the presence and extent of study variables including survival months depended on the SEER region collecting the data, as some regions provided active patient follow-up while some regions used recorded data to determine
survival status. The analysis was also constrained because the
SEER variable identifying sentinel lymph node biopsy versus
axillary lymph node dissection was found to be prone to underestimation due to data collection procedures, making the
data unavailable as a consideration in the current analysis [30].
However, the inaccurate collection procedures were rectified
in 2012 and should be included in future analysis of the utility
of lymph node dissection in cancer staging.
The focus in all the updates to the AJCC 8th edition guidelines is on cancers with the detectable biomarkers of ER, PR,
and HER2, and cases that are post-neoadjuvant therapy. Neoadjuvant therapies are systemic treatments that are now included in therapeutic recommendations to downstage cases of
advanced breast cancer prior to surgical intervention. Accurate staging of disease after the administration of neoadjuvant
therapy is even more imperative due to its predictive role in
determining risk of recurrence. Persistence of tumor growth
in lymph nodes despite prophylactic treatment warrants a
more strategic approach to treatment. For this reason, LNR is
worth considering as a supplementary staging technique for
the goal of attaining complete pathological response, which
means there is no evidence of invasive cancer left in the patient. This is only attained when the post-neoadjuvant AJCC
stage of the disease is T0/is and N0, meaning there is no primary tumor as well as no evidence of metastatic spread to the
https://doi.org/10.4048/jbc.2018.21.e35

axillary lymph nodes. Of note, the use of neoadjuvant therapies will likely decrease the number of cases staged as distant
metastasis, a consideration for the refinement of future LNR
research to be specific and attentive to regional node metastasis. The success of LNR for the prediction of survival in the
nebulous and possibly less predictable intermediate stages
warrants research into a supplementary role as the impact of
biologically-based intervention on prognosis changes the
landscape of breast oncology. Further investigation should
evaluate known breast cancer subtypes that exhibit aggressive
metastasis as well as survival rates for the concurrent usage of
the AJCC and LNR staging systems.
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